Buprenorphine/Naloxone sublingual - Taho Pharma
Alternative Names: Buprenorphine/Naloxone sublingual film - Taho Pharma; TAH-2211Latest Information Update: 31 Jul 2023
At a glance
- Originator TAHO Pharmaceuticals
- Class Antidotes; Benzofurans; Cyclopropanes; Drug withdrawal therapies; Isoquinolines; Morphinans; Opioid analgesics; Small molecules
- Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists; Opioid mu receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Opioid-related disorders
Most Recent Events
- 31 Jul 2023 Phase-I clinical trials in Opioid-related disorders in Taiwan (Sublingual), prior to July 2023 (Taho pharma pipeline, July 2023)